CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have received an average rating of “Moderate Buy” from the nineteen brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $65.4706.

A number of equities research analysts have commented on the company. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Evercore restated an “outperform” rating and issued a $76.00 target price on shares of CRISPR Therapeutics in a research report on Monday, May 11th. TD Cowen boosted their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a report on Friday, February 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. Finally, Sanford C. Bernstein boosted their price objective on CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the sale, the insider owned 19,357 shares in the company, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Samarth Kulkarni sold 10,020 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the sale, the chief executive officer owned 255,501 shares in the company, valued at $11,952,336.78. This represents a 3.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 33,937 shares of company stock worth $1,646,126. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mcguire Capital Advisors Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter worth $25,000. Ramirez Asset Management Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter worth $26,000. Rothschild Investment LLC grew its stake in CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its stake in CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after purchasing an additional 382 shares in the last quarter. Finally, Optiver Holding B.V. grew its stake in CRISPR Therapeutics by 71.4% during the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $49.44 on Friday. CRISPR Therapeutics has a 52 week low of $39.81 and a 52 week high of $78.48. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $4.77 billion, a P/E ratio of -7.95 and a beta of 1.74. The stock’s fifty day moving average is $52.33 and its two-hundred day moving average is $53.12.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The business had revenue of $1.46 million during the quarter. Equities analysts expect that CRISPR Therapeutics will post -4.92 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.